Multiple Sclerosis
📧 Sign up to get email alerts when something new happens for Multiple Sclerosis.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2023-08-28Clinical Trial Update: Efficacy and Safety of BG00012 in MS [Phase 2]
Phase 2 clinical trial update evaluating efficacy and safety of BG00012 in multiple sclerosis has completed.
-
FDA approval · 2023-08-24FDA Approved: TYRUKO — Original Application (Sandoz Inc)
FDA approved TYRUKO (natalizumab-sztn) from Sandoz Inc under an original Biologics License Application as a natalizumab biosimilar. The appr…
-
CLINICAL_TRIALS withdrawal · 2023-08-23Clinical Trial Update: The Effects of Ethyl-Alpha-Guanido-Methyl Ethanoate on Skin Reactions From Glatiramer Acetate Injections [Phase 4]
A Phase 4 trial investigating the effects of a compound on skin reactions from glatiramer acetate injections was withdrawn.
-
FDA approval · 2023-08-18FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)
The FDA approved a supplemental application for Ocrevus (ocrelizumab) from Genentech, Inc. The action expands the drug's approved indication…
-
CLINICAL_TRIALS trial_result · 2023-08-16Clinical Trial Update: Combined Effect of Transcranial Direct Current Stimulation (tDCS) and Physical Activity on Gait and Functional Mobility in Participants With Multiple Sclerosis [NA]
A completed clinical trial evaluating the combined effect of transcranial direct current stimulation (tDCS) and physical activity on gait an…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
FDA approval · 2023-08-10FDA Approved: MAYZENT — Supplemental Application (Novartis Pharmaceuticals Corporation)
FDA approves a supplemental application for Mayzent (siponimod) submitted by Novartis Pharmaceuticals Corporation to update the product labe…
-
FDA label_change · 2023-08-10FDA Approved: TASCENSO ODT — Supplemental Application (Cycle Pharmaceuticals Ltd)
FDA granted approval of a supplemental application for TASCENSO ODT, adding fingolimod lauryl sulfate as a new orodispersible tablet formula…
-
FDA approval · 2023-08-10FDA Approved: GILENYA — Supplemental Application (Novartis Pharmaceuticals Corporation)
The FDA approved a supplemental application for GILENYA (fingolimod HCL) submitted by Novartis Pharmaceuticals Corporation.
-
FDA approval · 2023-07-28FDA Approved: BETASERON — Supplemental Application (Bayer HealthCare Pharmaceuticals Inc.)
FDA approved a supplemental application for Betaseron (interferon beta-1b) submitted by Bayer HealthCare Pharmaceuticals Inc. This action up…
-
FDA approval · 2023-07-28FDA Approved: AVONEX — Supplemental Application (Biogen Inc.)
The FDA approved a supplemental application for AVONEX (interferon beta-1a) from Biogen. The action updates the labeling or approved indicat…
-
FDA approval · 2023-07-28FDA Approved: PLEGRIDY PEN — Supplemental Application (Biogen Inc.)
FDA approved a supplemental application for Plegridy Pen, a device for administering peginterferon beta-1a by Biogen.
-
FDA approval · 2023-07-28FDA Approved: REBIF — Supplemental Application (EMD Serono, Inc.)
FDA approved a supplemental application for Rebif (interferon beta-1a) submitted by EMD Serono, Inc.
-
CLINICAL_TRIALS trial_result · 2023-07-28Clinical Trial Update: Cladribine vs Placebo for Non-active Progressive Multiple Sclerosis (CLASP-MS). [Phase 2, Phase 3]
Clinical trial update for cladribine vs placebo in non-active progressive multiple sclerosis (CLASP-MS) is currently recruiting in Phase 2 a…
-
CLINICAL_TRIALS trial_result · 2023-07-20Clinical Trial Update: Safety and Tolerability of Conversion From Oral, Injectable, or Infusion Disease Modifying Therapies to Dose-titrated Oral Siponimod (Mayzent) in Advancing RMS Patients [Phase 3]
Phase 3 trial assessing safety and tolerability of converting relapsing multiple sclerosis patients from oral, injectable, or infusion disea…
-
FDA approval · 2023-07-05FDA Approved: GLATOPA — Supplemental Application (Sandoz Inc)
FDA approved Sandoz's supplemental application for GLATOPA, a generic glatiramer acetate product, for use in treating multiple sclerosis.
-
FDA approval · 2023-06-08FDA Approved: BACLOFEN — Original Application (Slayback Pharma LLC)
The FDA approved Slayback Pharma LLC's original application for a generic baclofen product for the treatment of spasticity associated with m…
-
CLINICAL_TRIALS trial_result · 2023-06-01Clinical Trial Update: Mesenchymal Stem Cells for Multiple Sclerosis [Phase 1, Phase 2]
Phase 1/2 clinical trial evaluating mesenchymal stem cells for multiple sclerosis has completed.
-
CLINICAL_TRIALS trial_result · 2023-05-16Clinical Trial Update: Effects of Physical Therapy and Dalfampridine on Functional Mobility in Non Ambulatory Persons With Multiple Sclerosis [Phase 2, Phase 3]
A phase 2/3 clinical trial evaluating the effects of physical therapy and dalfampridine on functional mobility in non-ambulatory people with…
-
FDA approval · 2023-05-15FDA Approved: TERIFLUNOMIDE — Original Application (Natco Pharma USA LLC)
FDA approved Natco Pharma USA LLC's original application for generic teriflunomide, a disease-modifying therapy for relapsing forms of multi…
-
CLINICAL_TRIALS trial_result · 2023-05-12Clinical Trial Update: e-Mobile Tablet for People With Chronic Conditions [NA]
Clinical trial update for an e-Mobile Tablet intervention in chronic conditions; the study is completed with results posted.
-
FDA approval · 2023-05-08FDA Approved: GLATOPA — Supplemental Application (Sandoz Inc)
The FDA approved a supplemental application for GLATOPA (glatiramer acetate) from Sandoz Inc, providing a generic version of glatiramer acet…
-
FDA approval · 2023-05-01FDA Approved: DALFAMPRIDINE — Supplemental Application (Aurobindo Pharma Limited)
FDA approved a supplemental application for dalfampridine from Aurobindo Pharma Limited, enabling a generic version of the drug. This action…
-
FDA approval · 2023-05-01FDA Approved: DALFAMPRIDINE — Supplemental Application (Accord Healthcare Inc.)
FDA approved Accord Healthcare Inc.'s supplemental application for dalfampridine, approving the generic dalfampridine product.
-
FDA approval · 2023-05-01FDA Approved: DALFAMPRIDINE — Supplemental Application (Ascend Laboratories, LLC)
The FDA approved a supplemental application for a generic dalfampridine product from Ascend Laboratories, LLC.
-
CLINICAL_TRIALS trial_result · 2023-04-28Clinical Trial Update: Non-inferiority Study of Rituximab Compared to Ocrelizumab in Relapsing MS [Phase 3]
Non-inferiority Phase 3 trial comparing rituximab to ocrelizumab in relapsing multiple sclerosis is currently recruiting.